الفهرس 
Pathophysiology of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE)Only 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
The aim of this essay was to discuss the role of new oral anticoagulant in treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in comparison with the traditional anticoagulants.
Thromboembolic disorders are a major cause of morbidity and mortality worldwide. Venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder after ischaemic heart disease and stroke, and is estimated to contribute to about 10% of all deaths that occur in the hospital.
Now three oral anticoagulant drugs are FDA-approved in treatment and prevention of recurrence of deep venous thrombosis (DVT) and pulmonary embolism (PE), these drugs are (rivaroxiban, dabigatran, apixaban), the fourth one (edoxaban) still under Food and Drug Administration (FDA) review.